Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity

Therapeutic targeting of the VEGF signaling axis by the VEGF-neutralizing monoclonal antibody bevacizumab has clearly demonstrated clinical benefit in cancer patients. To improve this strategy using a polyclonal approach, we developed a vaccine targeting VEGF using 3D-structured peptides that mimic...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Proc Natl Acad Sci U S A
Главные авторы: Wentink, Madelon Q., Hackeng, Tilman M., Tabruyn, Sebastien P., Puijk, Wouter C., Schwamborn, Klaus, Altschuh, Daniele, Meloen, Rob H., Schuurman, Teun, Griffioen, Arjan W., Timmerman, Peter
Формат: Artigo
Язык:Inglês
Опубликовано: National Academy of Sciences 2016
Предметы:
Biological Sciences
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5098619/
https://ncbi.nlm.nih.gov/pubmed/27791128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1610258113
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы